Among intensive care unit (ICU) patients with hypovolemia, treatment with colloids vs crystalloids was associated with similar 28-day mortality, according to a multicenter, randomized clinical trial ...

Centhaquine, a new drug to treat patients who have severe blood or fluid loss, significantly improved outcomes and reduced death rate among shock patients. Centhaquine significantly improved survival ...

Septic shock results in approximately 350,000 deaths in the U.S. each year, the leading cause of hospital-related mortality and a major financial burden for the medical system Six trial sites with ...

Dr Reddy's and Pharmazz are collaborating to roll out Centhaquine, a revolutionary resuscitative agent for hypovolemic shock in India. The drug aims to improve cardiac output and blood circulation, ...

KANSAS CITY, Mo.--(BUSINESS WIRE)--Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and hemorrhagic ...

Drugmaker Dr. Reddy’s Laboratories has signed a licensing agreement to market U.S. biopharmaceutical company Pharmazz’s Centhaquine, a ‘first-of-its-kind’ resuscitative agent to treat hypovolemic ...

Extensive rhabdomyolysis is often lethal unless treated immediately. Early mortality arises from hypovolemic shock, hyperkalemia, acidosis and myoglobinuric acute kidney injury (AKI). Many individuals ...

Hemorrhagic shock can occur after losing a significant amount of blood. Both internal and external bleeding can cause it. Hemorrhagic shock is life threatening and requires immediate medical attention ...

Septic shock results in approximately 350,000 deaths in the U.S. each year, the leading cause of hospital-related mortality and a major financial burden for the medical system Absolute hypovolemia ...

KANSAS CITY, Mo., Sept. 3, 2024 /PRNewswire/ -- Vivacelle Bio, a late-stage biopharma company developing life-saving treatments for shock and trauma, today announced that it has enrolled the first ...